ArticleInternational journal of general medicine2025
Prognostic Significance of Serum NLRP3 in Spontaneous Intracerebral Hemorrhage.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glucocorticoids combined with anticoagulation modulate the central NLRP3/NETosis inflammatory process in patients with severe cerebral venous thrombosis: a human mechanistic exploratory study.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Ginsenoside Rg2 attenuates secondary brain injury following intracerebral hemorrhage by inhibiting NLRP3-mediated pyroptosis.Journal of neuroinflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) is involved in secondary brain injury after acute intracerebral hemorrhage (ICH). The objective of this study was to determine its ability to predict early neurological deterioration (END) and 3-month neurological outcome after ICH. Methods: In this prospective cohort study, serum NLRP3 levels were measured in 128 patients with sICH and 100 healthy controls. National institute of health stroke scale (NIHSS) scores and hematoma volumes were recorded. Post-ICH END and 3-month poor outcome (modified Rankin Scale (mRS) scores of 3-6) were documented. The results were assessed using multivariate analysis. Results: Serum NLRP3 levels in sICH patients increased significantly as compared to controls (P<0.001). Serum NLRP3 levels were independently correlated with hematoma volumes (β=0.046; 95% confidence interval (CI), 0.020-0.072; P=0.001) and NIHSS scores (β=0.071; 95% CI, 0.004-0.139; P=0.039), independently forecasted END (OR=1.268; 95% CI, 0.892-1.801; P=0.036) and poor prognosis at post-ICH 3 months (OR=1.448; 95% CI, 1.006-2.085; P=0.046), and were predictive of them with areas under receiver operating characteristic curve at 0.788 (95% CI, 0.706-0.855) and 0.805 (95% CI, 0.725-0.870) separately. Serum NLRP3 levels, along with the two independent predictors, that are NIHSS scores and hematoma volumes, are combined to establish prediction models of END and poor prognosis. The models worked well by applying a series of statistical methods. Conclusion: Increased serum NLRP3 levels after ICH are independently associated with bleeding severity, END and adverse outcomes of patients, meaning that serum NLRP3 may be a potential prognostic biomarker of sICH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.